Log in  First Connection?

Others Urological ConditionsArchives

In vitro efficacy of ceftazidime/avibactam and cefiderocol against multidrug-resistant Gram-negative uropathogens: insights into ?-lactamase-mediated resistance in clinical isolates

 Published on 03/07/2026 |  Original article (Full-text)  | Ibrahim, Mohamed A. et al. | Future Journal of Pharmaceutical Sciences. Volume 12(1).

Urinary tract infections (UTIs) are among the most common bacterial infections in hospitalized patients, frequently caused by Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa. The increasing prevalence...

The role of plant-derived compounds in the management and prevention of urolithiasis: a review of evidence and mechanisms

 Published on 26/06/2026 |  Original article (Full-text)  | Chamodini, A. G. K. et al. | Clinical Phytoscience. Volume 12(1).

Urolithiasis, the condition of forming stones in the urinary system, is a common health problem worldwide and tends to recur. Pathophysiology includes stages such as supersaturation, nucleation, growth, aggregation, and crystal-cell interactions. Most conventional treatments have disadvantages of failing...

Rapid and accurate preoperative diagnosis of urinary tract infections in urolithiasis patients: clinical validation of the HB&L system

 Published on 19/06/2026 |  Original article (Full-text)  | Chang Zhenglin et al. | BMC Infectious Diseases 2025; 26(1): 247

Urinary tract infections (UTIs) represent a significant clinical challenge in patients with urolithiasis [1], with infection rates reported between 7 and 28% of stone formers [2], increasing hospitalization duration and treatment costs substantially when complications arise. The management of these infections...

Comparing the clinical accuracy of urine exfoliated cell examination and fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma

 Published on 12/06/2026 |  Original article (Full-text)  | Wang Chundan et al. | BMC Urology 2025; 26(1): 32

Upper urinary tract urothelial carcinoma (UTUC), which refers to renal pelvis cancer and ureteral cancer, is a rare malignant tumor that comprises 5% to 10% of all urothelial tumors. Based on statistics, UTUC has an incidence of approximately 2/100,000, or 2 per 100,000 of the general population [1,...

Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing

 Published on 05/06/2026 |  Original article (Full-text)  | Abdul Rahman Al Armashi et al. | Expert Review of Anticancer Therapy 2026; aop:10.1080/14737140.2026.2628071

Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utility, and treatment discontinuation from toxicity remains problematic. This article integrates clinical...